Eli Lilly, Johnson & Johnson and GlaxoSmithKline headline the second annual edition of the Outcomes Creativity Index (OCI), a ranking of pharmaceutical companies and prescription brands according to creativity and innovation. The OCI is an aggregate score-based creative achievement encompassing results from eight leading U.S. and international healthcare awards shows that are tabulated to rank the top 10 pharmaceutical companies and top 10 prescription brands.
2019 was a good year for the pharma industry, even as questions on value kept coming; but 2020 brought a pandemic that raised an “all hands on deck” attitude as well as business challenges.
The Outcomes Creativity Index (OCI) represents a ranking of pharmaceutical companies and brands according to creativity and innovation. The OCI is an aggregate score-based creative achievement representing these leading U.S. and international healthcare award shows: The Outcomes LLC/Med Ad News Manny Awards; Cannes Lions; LIA: Health & Wellness; Clio Health; The One Show; The MM&M Awards; The Global Awards; and The Creative Floor Awards.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
The executive management team of this “132-year-old startup” company is excited about a future that lies beyond the intersection of science and technology.